Related Experiment Video
Updated: Apr 5, 2026

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
Published on: September 17, 2019
A Versatile Monoclonal Antibody Specific Against Human DAB2IP.
Yintao Su1, Fangyuan Shi2, Zhanzhuang Zeng3
11 State Key Laboratory of Structural Chemistry, Fujian Institute of Research on the Structure of Matter , Chinese Academy of Sciences, Fuzhou, China .
Researchers developed a novel monoclonal antibody, 2A4, targeting human DAB2 interaction protein (DAB2IP). This antibody is a valuable tool for studying DAB2IP
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Human DAB2 interaction protein (DAB2IP) is a Ras-GTPase activating protein family member.
- DAB2IP functions as a tumor suppressor, suggesting its potential as a cancer prognostic biomarker.
Purpose of the Study:
- To generate a specific monoclonal antibody against human DAB2IP.
- To validate the antibody as a tool for DAB2IP research and biomarker development.
Main Methods:
- Generation of a mouse monoclonal antibody (2A4) against human DAB2IP.
- Characterization of the antibody's specificity for both native and denatured DAB2IP.
- Isotyping the antibody as IgG1.
Main Results:
- A specific monoclonal antibody, 2A4, was successfully generated against human DAB2IP.
- The antibody recognizes human DAB2IP in both native and denatured states.
- The antibody was confirmed to be of the IgG1 isotype.
Conclusions:
- The 2A4 antibody is a specific and versatile tool for studying human DAB2IP.
- This antibody will facilitate further research into the mechanisms of DAB2IP.
- The antibody supports the investigation of DAB2IP's prognostic significance in cancers.
More Related Videos
13:21Chemically-blocked Antibody Microarray for Multiplexed High-throughput Profiling of Specific Protein Glycosylation in Complex Samples
Published on: May 4, 2012
13:14Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood
Published on: February 6, 2018